FDA-Approved Poteligeo for Two Types of Cutaneous T-cell Lymphoma
News
The U.S. Food and Drug Administration’s (FDA) recent approval of Poteligeo (mogamulizumab-kpkc) was based on a Phase 3 trial that showed Poteligeo significantly slowed disease progression in adults with relapsed or ... Read more